Chemerin: A potential target in Coronary Artery Disease A Review

Authors

  • Anand Duraiswamy Frontier lifeline Hospital,Dr.K.M.Cherian heart Foundation, Mogappair, chennai, Tamilnadu,India
  • Sheela Sasikumar Chief scientific officer, Frontier lifeline Hospital, Dr.K.M.Cherian heart Foundation, Mogappair, chennai, Tamilnadu,India
  • Devanand Shanmugasundaram Frontier lifeline Hospital, Dr.K.M.Cherian heart Foundation, Mogappair, Chennai, Tamilnadu
  • Kotturathu Mammen Cherian Frontier lifeline Hospital, Dr.K.M.Cherian heart Foundation, Mogappair, Chennai, Tamilnadu

DOI:

https://doi.org/10.7439/ijbar.v3i7.598

Abstract

Currently, Coronary Artery Disease (CAD) is considered as a major ailment in humans with widespread prevalence. CAD also accounts for high mortality rates around the world that involves several known risk factors. Recently, it was discovered that epicardial adipose tissue (EAT) and its secretory adipokines play an imperative role in the development of CAD. Among the secretory adipokines, chemerin , a serpentine chemotactic agonist has been identified as one of the factor which contributes for the progression of CAD. Since serum chemerin levels are elevated during CAD condition, it is being considered to be a valiant marker but then the chimeric property of chemerin is yet to be explored. Though chemerin has been identified as one of the factors responsible for the development of CAD, it is still being studied at the marker level. This review aims to study whether chemerin can only be used as a marker or can it also be used as a novel target for treating or suppressing or delaying the progression of coronary artery disease.

Downloads

Download data is not yet available.

Author Biographies

  • Anand Duraiswamy, Frontier lifeline Hospital,Dr.K.M.Cherian heart Foundation, Mogappair, chennai, Tamilnadu,India
    PhD research scholarDept of Biochemistry
  • Sheela Sasikumar, Chief scientific officer, Frontier lifeline Hospital, Dr.K.M.Cherian heart Foundation, Mogappair, chennai, Tamilnadu,India
    Department of biochemistryChief scientific officer
  • Devanand Shanmugasundaram, Frontier lifeline Hospital, Dr.K.M.Cherian heart Foundation, Mogappair, Chennai, Tamilnadu
    PhD research scholarDept of Biochemistry
  • Kotturathu Mammen Cherian, Frontier lifeline Hospital, Dr.K.M.Cherian heart Foundation, Mogappair, Chennai, Tamilnadu
    Director & CEO

Downloads

Published

2012-08-01

Issue

Vol. 3 No. 7 (2012): July

Section

Review Article

License

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).

How to Cite

Chemerin: A potential target in Coronary Artery Disease A Review. (2012). International Journal of Biomedical and Advance Research, 3(7), 537-540. https://doi.org/10.7439/ijbar.v3i7.598
Crossref
Scopus
Google Scholar
Europe PMC